Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies
This open, single-arm, exploratory study looked at the efficacy and safety of apatinib in combination with S-1 as second-line treatment of advanced head and neck malignancies.
Head and Neck Cancer
DRUG: Apatinib
PFS, Progression free survival, 40 months
OS, Overall survival, 40 months
This open, single-arm, exploratory study looked at the efficacy and safety of apatinib in combination with S-1 as second-line treatment of advanced head and neck malignancies.